Our previous study found that REV-ERBα switches its physiological function from a repressor to a master activator in adenocarcinoma of PCa and liver cancer to directly control multiple tumorigenic programs including MAPK and PI3K-Akt signaling, through partnering with BRD4/p300 coactivators and FOXA1 (39). This evidence concerns the gene NR1D1 and adenocarcinoma.